Search results
Study shows new cancer vaccine to treat melanoma has 96% survival rate
UNILAD· 5 days agoA new vaccine treatment for skin cancer melanoma has shown extremely promising results in a new ...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 6 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 6 days ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 6 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 4 days agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 6 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoThat compares to 55.6% for Keytruda alone. Earlier in the year, one analyst called results from the...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 6 days agoModerna (NASDAQ:MRNA) and Merck (MRK) have released new, more encouraging three-year data on their...
3 Reasons to Buy Moderna Stock | The Motley Fool
The Motley Fool· 1 day agoAlthough Moderna (MRNA -2.38%) is now a somewhat famous biotech, it was a relatively unknown, clinical-stage company just five years ago. Is Moderna just...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 6 days agoCancer vaccines are finally showing promise as Moderna and Merck touted promising data on an...